Launched in May of 2010, it only took two years for Oncotarget to reach an impact factor of 6.67, and by 2015, Oncotarget had more published documents than any other oncology journal. Quickly becoming one of the best places to submit research papers, Oncotarget’s rapid peer-review process eliminates the lengthy, demoralizing road to publication; typically, authors will receive an editorial decision in one to four days.
While some journals make months to review papers, Oncotarget found that having the author’s work go straight to the editors, not to the journal’s managers, significantly speeds up the process. Oncotarget’s policy is not to ask for additional experiments unless the paper is likely to be published if the experiments are completed. Asking contributors to perform unnecessary experiments wastes their time and money, especially if the paper is ultimately rejected. Download output styles at Endnote.com.
Oconotarget also accepts research papers on cell biology, pharmacology, microbiology and more. Each sub-section section has its own editor and editorial advisory board. The Editorial Boards consists of prominent scientists from Harvard Medical School, Emory University, The Scripps Research Institute and other eminent institutions. Both editors-in-chief, Andrei V. Gudkov and Mikhail V. Blagosklonny, are from the Roswell Park Cancer Institute.
Sharing scientific results quickly and making the information easily accessible allows others to build on the research and apply the methodology in new ways, which ultimately benefits cancer patients waiting for more effective treatment options. Oncotarget utilizes the Creative Commons Attribution License for published work, therefore, everyone is free to read, download and use all works, as long as they cite the authors and Oncotarget. Oncotarget, which is published by Impact Journals